<DOC>
	<DOCNO>NCT01905540</DOCNO>
	<brief_summary>This study evaluate relative bioavailability new SSP-004184SS capsule formulation compare original SSP-004184AQ drug plus excipients formulation .</brief_summary>
	<brief_title>A Relative Bioavailability Study SSP-004184AQ ( Magnesium Salt ) SSP-004184SS ( Disodium Salt )</brief_title>
	<detailed_description />
	<criteria>Age 1865 year Must consider `` healthy '' . Serum ferritin &gt; 20ng/mL , hemoglobin &gt; 125g/L erythrocyte index within normal range Subject clinically significant history disorder detect medical interview/physical examination Screening Visit medical condition capable alter absorption , metabolism , elimination drug Acute illness , judge investigator , within 2 week Day 1 Treatment Period 1 . Known suspected intolerance hypersensitivity investigational product , closely related compound , state ingredient . Subject history thyroid disorder stabilize thyroid medication treatment within 3 month History alcohol substance abuse within last year . A positive screen alcohol drug abuse Screening Visit . Confirmed systolic blood pressure &gt; 139mmHg &lt; 89mmHg , diastolic blood pressure &gt; 89mmHg &lt; 49mmHg . Twelvelead ECG demonstrate QTc &gt; 450msec screening . Routine consumption 2 unit caffeine per day subject experience caffeine withdrawal headache . Male subject consume 3 unit alcohol per day . Female subject consume 2 unit alcohol per day . A positive HIV antibody screen , HBsAg , HCV antibody screen . Use tobacco form ( eg , smoke chew ) nicotinecontaining product form ( eg , gum , patch ) within 30 day prior Day 1 Treatment Period 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>